A Phase 1 interventional study of Ertugliflozin 15 mg in Type 2 Diabetes Mellitus and Hepatic Impairment, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-08-20.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 — 3 open to participants now, 3 under way, none of them phase 3. ertugliflozin · Diabetes Mellitus, Type 2.
Among the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, this one is the 25th largest by enrollment, is one of 4 that started in 2014, is one of 8 in phase 1, and was the 15th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Amsterdam UMC, location VUmc · Sites in United States, Netherlands
Ages 18–85
Baylor Research Institute · Sites in United States
Ages 18–84
Shanghai Zhongshan Hospital · Sites in China
Ages 19+
By country, each count listing its studies:
ertugliflozin: first FDA approval 2017 (STEGLATRO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 4 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 83 across the 28 interventional studies. Of the 24 that completed or were terminated, 19 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 28 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 154th largest by enrollment of the 170 interventional ones that give a count, is one of 6 that started in 2014, is one of 55 in phase 1, and was the 163rd registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a study to assess the pharmacokinetics and safety of ertugliflozin (MK-8835, PF-04971729) in participants with hepatic impairment versus healthy participants. In Part 1 of the study, participants with moderate hepatic impairment (Child-Pugh score 7-9) and matched healthy participants will be enrolled; depending on results in Part 1, Part 2 may be conducted and will enroll participants with mild hepatic impairment (Child-Pugh score 5-6).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
ALL PARTICIPANTS:
Exclusion Criteria:
ALL PARTICIPANTS
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive a single 15 mg oral dose (tablet) of ertugliflozin
Drug: Ertugliflozin 15 mg
Participants receive a single 15 mg oral dose (tablet) of ertugliflozin
Drug: Ertugliflozin 15 mg
Participants receive a single 15 mg oral dose (tablet) of ertugliflozin
Drug: Ertugliflozin 15 mg
Tablet
Area Under the Plasma Concentration-Time Curve From Time 0 to Time of the Last Quantifiable Concentration (AUClast) for Ertugliflozin
Area under the plasma concentration-time profile from time zero to time of the last quantifiable concentration (AUClast).
Time frame: Hour 0 (predose), and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours
AUC From Hour 0 to Infinity (AUCinf) for Ertugliflozin
Area under the plasma concentration-time profile from time zero extrapolated to infinite time (AUCinf).
Time frame: Hour 0 (predose), and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours
AUClast for Fraction of Ertugliflozin Unbound in Plasma (AUClast,u)
Area under the plasma concentration-time profile from time zero to time of the last quantifiable concentration (Clast) for unbound drug (ertugliflozin only).
Time frame: Hour 0 (predose), and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours
AUCinf for Fraction of Ertugliflozin Unbound in Plasma (AUCinf,u)
Area under the plasma concentration-time profile from time zero extrapolated to infinite time for unbound drug (ertugliflozin only) (AUCinf, u).
Time frame: Hour 0 (predose), and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours
Maximum Plasma Concentration (Cmax) of Ertugliflozin
Cmax is a measure of the maximum amount of drug in the plasma after the dose is given.
Time frame: Hour 0 (predose), and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours
Cmax for Fraction of Ertugliflozin Unbound in Plasma (Cmax,u)
Maximum plasma concentration for unbound drug (ertugliflozin only).
Time frame: Hour 0 (predose), and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours
Number of Participants Who Experienced an Adverse Event
An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
Time frame: Up to 19 days
Based on a statistical evaluation of the pharmacokinetic (PK) data obtained from participants with moderate hepatic impairment and matched healthy volunteers, and the pre-specified decision criteria, Part 2 of the study was not conducted and participants with mild hepatic impairment were not enrolled.
| Milestone | Ertugliflozin 15 mg (Moderate Hepatic Impairment) | Ertugliflozin 15 mg (Normal Hepatic Function) | Ertugliflozin 15 mg - Mild Hepatic Impairment |
|---|---|---|---|
| Started | 8 | 8 | 0 |
| Completed | 8 | 8 | 0 |
| Not completed | 0 | 0 | 0 |
Area under the plasma concentration-time profile from time zero to time of the last quantifiable concentration (AUClast).
| ng•hr/mL | Ertugliflozin 15 mg (Moderate Hepatic Impairment) | Ertugliflozin 15 mg (Normal Hepatic Function) |
|---|---|---|
| Area Under the Plasma Concentration-Time Curve From Time 0 to Time of the Last Quantifiable Concentration (AUClast) for Ertugliflozin | 1413 ± 39 | 1618 ± 14 |
Area under the plasma concentration-time profile from time zero extrapolated to infinite time (AUCinf).
| ng•hr/mL | Ertugliflozin 15 mg (Moderate Hepatic Impairment) | Ertugliflozin 15 mg (Normal Hepatic Function) |
|---|---|---|
| AUC From Hour 0 to Infinity (AUCinf) for Ertugliflozin | 1430 ± 39 | 1636 ± 14 |
Area under the plasma concentration-time profile from time zero to time of the last quantifiable concentration (Clast) for unbound drug (ertugliflozin only).
| ng•hr/mL | Ertugliflozin 15 mg (Moderate Hepatic Impairment) | Ertugliflozin 15 mg (Normal Hepatic Function) |
|---|---|---|
| AUClast for Fraction of Ertugliflozin Unbound in Plasma (AUClast,u) | 52.47 ± 44 | 54.77 ± 15 |
Area under the plasma concentration-time profile from time zero extrapolated to infinite time for unbound drug (ertugliflozin only) (AUCinf, u).
| ng•hr/mL | Ertugliflozin 15 mg (Moderate Hepatic Impairment) | Ertugliflozin 15 mg (Normal Hepatic Function) |
|---|---|---|
| AUCinf for Fraction of Ertugliflozin Unbound in Plasma (AUCinf,u) | 53.14 ± 44 | 55.40 ± 16 |
Cmax is a measure of the maximum amount of drug in the plasma after the dose is given.
| ng/mL | Ertugliflozin 15 mg (Moderate Hepatic Impairment) | Ertugliflozin 15 mg (Normal Hepatic Function) |
|---|---|---|
| Maximum Plasma Concentration (Cmax) of Ertugliflozin | 251.1 ± 27 | 319.0 ± 11 |
Maximum plasma concentration for unbound drug (ertugliflozin only).
| ng/mL | Ertugliflozin 15 mg (Moderate Hepatic Impairment) | Ertugliflozin 15 mg (Normal Hepatic Function) |
|---|---|---|
| Cmax for Fraction of Ertugliflozin Unbound in Plasma (Cmax,u) | 9.336 ± 30 | 10.79 ± 15 |
An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
| Participants | Ertugliflozin 15 mg (Moderate Hepatic Impairment) | Ertugliflozin 15 mg (Normal Hepatic Function) |
|---|---|---|
| Number of Participants Who Experienced an Adverse Event | 2 | 3 |
Collected over Up to Day 19. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ertugliflozin 15 mg (Moderate Hepatic Impairment) | — | 0/8 (0%) | 2/8 (25%) |
| Ertugliflozin 15 mg (Normal Hepatic Function) | — | 0/8 (0%) | 3/8 (37.5%) |
| Event | Ertugliflozin 15 mg (Moderate Hepatic Impairment) | Ertugliflozin 15 mg (Normal Hepatic Function) |
|---|---|---|
| TachycardiaCardiac disorders | 1/8 | 0/8 |
| NauseaGastrointestinal disorders | 0/8 | 1/8 |
| FuruncleInfections and infestations | 0/8 | 1/8 |
| Decreased appetiteMetabolism and nutrition disorders | 1/8 | 0/8 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/8 | 1/8 |
| Back painMusculoskeletal and connective tissue disorders | 0/8 | 1/8 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/8 | 1/8 |
| DizzinessNervous system disorders | 0/8 | 1/8 |
| HeadacheNervous system disorders | 1/8 | 0/8 |
| ParaesthesiaNervous system disorders | 0/8 | 1/8 |
The PK concentration population was defined as all participants treated who had at least 1 concentration measurement. Based on evaluation of the PK data from participants with moderate hepatic impairment and matched healthy volunteers, Part 2 of the study was not conducted and participants with mild hepatic impairment were not enrolled.
| Age, Continuous(Years) | Ertugliflozin 15 mg (Moderate Hepatic Impairment) | Ertugliflozin 15 mg (Normal Hepatic Function) | Total |
|---|---|---|---|
| Mean | 55.1 ± 3.4 | 55.5 ± 3.0 | 55.3 (49 to 60) |
| Sex: Female, Male(Participants) | Ertugliflozin 15 mg (Moderate Hepatic Impairment) | Ertugliflozin 15 mg (Normal Hepatic Function) | Total |
|---|---|---|---|
| Female | 4 | 4 | 8 |
| Male | 4 | 4 | 8 |
No study locations are listed for this record.
Ran from Sep 2014 to primary completion in Jan 2015, 3 months.
Results were first posted in Aug 2018, 3 years 6 months after primary completion.
Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 3 months is below that.
Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ertugliflozin